Mumbai, Dec. 19 -- Pfizer India and Cipla Limited on Friday announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India.

Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, the proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India.

Notably, Dalacin C is a part of Pfizer Products India Pvt. Ltd; Corex Dx; Corex LS, Dolonex and Neksium are a part of Pfizer Ltd.

Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.

Meenakshi Nevatia, Country President, Pfizer India, said, "At Pfizer, expanding the reach of o...